Serum cytokine profiles in patients with prostate carcinoma

Experimental and Therapeutic Medicine

Volumn 2, Issue 5, 2011, Pages 887-891

  Tazaki, Eri ^a   Shimizu, Nobuaki ^b   Tanaka, Ryota ^a   Yoshizumi, Masakazu ^c   Kamma, Hiroshi ^a   Imoto, Shigeru ^a   Goya, Tomoyuki ^a   Kozawa, Kunihisa ^c   Nishina, Atsuyoshi ^d   Kimura, Hirokazu ^e  

^a KYORIN UNIVERSITY   (Japan)

^b GUNMA PREFECTURAL CANCER CENTER   (Japan)

^c GUNMA PREFECTURAL INSTITUTE OF PUBLIC HEALTH AND ENVIRONMENTAL SCIENCES   (Japan)

^d Yonezawa Women's Junior College   (Japan)

^e NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Cachexia; Cytokine; Cytokine profiles; Prostate carcinoma

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CACHEXIA; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLUORESCENCE ANALYSIS; HUMAN; INFLAMMATION; MALE; NEUTROPHIL CHEMOTAXIS; PATHOPHYSIOLOGY; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TH1 CELL; TH2 CELL;

EID: 79960220872     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.286     Document Type: Article

References (29)

1. Nelson WG: Prostate cancer prevention. Curr Opin Urol 17: 157-167, 2007.
2. Eble JN, Sauter G, Epstein JI and Sesterhenn IA (eds): Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs; World Health Organization Classification of Tumours. International Agency for Research on Cancer (IARC) Press, Lyon, 2004.
3. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
4. Argilés JM, Meijsing SH, Pallarés-Trujillo J, Guirao X and López-Soriano FJ: Cancer cachexia: a therapeutic approach. Med Res Rev 1: 83-101, 2001.
5. Tisdale MJ: Biology of cachexia. J Natl Cancer Inst 89: 1763-1773, 1997.
6. Davis MP and Dickerson D: Cachexia and anorexia: cancer's covert killer. Support Care Cancer 8: 180-187, 2000.
7. Smith KC, Bateman AC, Fussell HM and Howell WM: Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31: 167-173, 2004.
8. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, Roques S and Lazennec G: Oestrogen receptor-negative breast cancers exhibit high cytokine content. Breast Cancer Res 9: R15, 2007.
9. Suzuki S, Mita S, Kamohara H, Sakamoto K, Ishiko T and Ogawa M: IL-6 and IFN-gamma regulation of IL-10 production by human colon carcinoma cells. Int J Oncol 18: 581-586, 2001.
10. Szaflarska A, Szczepanik A, Siedlar M, Czupryna A, Sierzega M, Popiela T and Zembala M: Preoperative plasma level of IL-10 but not of proinflammatory cytokines is an independent prognostic factor in patients with gastric cancer. Anticancer Res 29: 5005-5012, 2009.
11. Kuroda K, Nakashima J, Kanao K, Kikuchi E, Miyajima A, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T and Murai M: Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 69: 113-117, 2007.
12. Tisdale MJ: New cachexic factors. Curr Opin Clin Nutr Metab Care 3: 253-256, 1998.
13. Nakashima J, Tachibana M, Ueno M, Miyajima A, Baba S and Murai M: Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res 7: 1743-1748, 1998.
14. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr and Corey E: Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97: 1211-1216, 2003.
15. Filella X, Alcover J, Zarco MA, Beardo P, Molina R and Ballesta AM: Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate 44: 271-274, 2000.
16. Wang M, Hu Y and Stearns ME: A novel IL-10 signalling mechanism regulates TIMP-1 expression in human prostate tumour cells. Br J Cancer 88: 1605-1614, 2003.
17. Vindrieux D, Escobar P and Lazennec G: Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 3: 663-673, 2009.
18. Giri D, Ozen M and Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159: 2159-2165, 2001.
19. Bouraoui Y, Ricote M, García-Tuñón I, Rodriguez-Berriguete G, Touffehi M, Rais NB, Fraile B, Paniagua R, Oueslati R and Royuela M: Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer. Cancer Detect Prev 32: 23-32, 2008.
20. Berry SJ, Coffey DS, Walsh PC and Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 132: 474-479, 1984.
21. Barnes PJ: The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 118: 3546-3556, 2008.
22. Kim SJ, Uehara H, Karashima T, McCarty M, Shih N and Fidler IJ: Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 3: 33-42, 2001.
23. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA and Dinney CP: Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6: 2104-2119, 2000.
24. Gelin J, Moldawer LL, Lönnroth C, Sherry B, Chizzonite R and Lundholm K: Role of endogenous tumor necrosis factor α and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 51: 415-421, 1991.
25. Fandrey J and Jelkmann WE: Interleukin-1 and tumor necrosis factor α inhibit erythropoietin production in vitro. Ann NY Acad Sci 628: 250-255, 1991.
26. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G and Anichini A: Interleukin-12: Biological properties and clinical application. Clin Cancer Res 13: 4677-4685, 2007.
27. Sangro B, Melero I, Qian C and Prieto J: Gene therapy of cancer based on interleukin 12. Currt Gene Ther 5: 573-581, 2005.
28. Mocellin S, Marincola FM and Young HA: Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78: 1043-1051, 2005.
29. Quatan N, Meyer B, Bailey M and Pandha H: Persistently high levels of immunosuppressive cytokines in patients after radical prostatectomy. Prostate Cancer Prostatic Dis 9: 420-425, 2006.